Large U.S. corporations are increasingly covering the costs of GLP-1 weight-loss medications for employees, viewing obesity as a significant factor in lost productivity and absenteeism. Companies are incorporating these treatments, originally designed for diabetes management, into their standard employee health benefit packages.
The Scope of Corporate Spending
Major financial institutions, including Bank of America, have begun allocating portions of their annual healthcare budgets to address obesity-related health issues. Reports indicate that Bank of America now directs approximately 13% of its yearly healthcare budget—totaling roughly $250 million—toward funding GLP-1 treatments for staff members diagnosed with obesity or diabetes.
Treatment Options Covered
The initiatives primarily focus on providing access to medications such as Ozempic, Wegovy, and Mounjaro. While Ozempic was initially developed and prescribed for patients managing diabetes, its use has expanded to include weight management. Corporations are now treating these medications as a necessary intervention to improve the overall health profile of their workforce.
Implications for Global Workforce Health
Medical experts have increasingly labeled obesity as a chronic disease and a significant epidemic of the 21st century. As corporations in the United States implement these funding models to mitigate the economic impact of chronic illness, global observers are evaluating whether similar health benefit structures could be adopted in other markets, such as Spain, where healthcare systems and corporate structures differ significantly.
Current Status of Corporate Health Benefits
The trend highlights a shift in how large employers manage human capital costs, moving from reactive sick leave policies to proactive chronic disease management. By subsidizing expensive medical treatments, companies aim to reduce long-term costs associated with absenteeism and decreased output.